Overview
Primary objective:
- Describe the characteristics of enrolled severe asthma patients
Secondary objectives:
- Assess the control of asthma under dupilumab (Dupixent®) treatment until 1 year
- Assess the clinical objectives of the asthma care
- Assess comorbidities associated with Type 2 inflammation
- Assess safety during the year of treatment
Description
52 weeks
Eligibility
Inclusion Criteria:
- Adolescents, for whom initiation of dupilumab (Dupixent®) for the severe uncontrolled asthma indication was decided by the investigator before the inclusion in the study
- Adolescents ≥ 12 and < 18 years of age at the time of the initiation of Dupixent® treatment
Exclusion Criteria:
- Adult participants ≥ 18 years of age
The above information is not intended to contain all considerations relevant to a potential
participation in a clinical trial.